Jaclyn Lopiccolo1, Shigeru Kawabata2, Joell J Gills2, Phillip A Dennis2. 1. Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, U.S.A. 2. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.
Abstract
BACKGROUND/AIM: Nelfinavir is a human immunodeficiency virus protease inhibitor that is currently being repositioned as an anticancer drug. Chloroquine, an anti-malarial lysosomotropic drug, inhibits autophagy. It has been reported that the combination of nelfinavir and chloroquine significantly enhances endoplasmic reticulum (ER) stress and induces selective cell death in multiple cell line models (in vitro). MATERIALS AND METHODS: We assessed the effects of the combination of these drugs on human NSCLC cell lines in vitro using cell proliferation assay and performed preclinical treatment studies using cell line-derived xenograft mouse models in vivo. RESULTS: In vitro, this combination enhanced inhibition of NSCLC cell proliferation with increased proteotoxicity, including ER stress, and apoptosis. In vivo, the growth of human NSCLC xenograft tumors was inhibited, which correlated with increased apoptosis and induction of ER stress as well as NSCLC growth in vitro. CONCLUSION: Our findings suggest that the induction of proteotoxicity provides a promising new target for developing anticancer drugs. Copyright
BACKGROUND/AIM: Nelfinavir is a human immunodeficiency virus protease inhibitor that is currently being repositioned as an anticancer drug. Chloroquine, an anti-malarial lysosomotropic drug, inhibits autophagy. It has been reported that the combination of nelfinavir and chloroquine significantly enhances endoplasmic reticulum (ER) stress and induces selective cell death in multiple cell line models (in vitro). MATERIALS AND METHODS: We assessed the effects of the combination of these drugs on humanNSCLC cell lines in vitro using cell proliferation assay and performed preclinical treatment studies using cell line-derived xenograft mouse models in vivo. RESULTS: In vitro, this combination enhanced inhibition of NSCLC cell proliferation with increased proteotoxicity, including ER stress, and apoptosis. In vivo, the growth of humanNSCLC xenograft tumors was inhibited, which correlated with increased apoptosis and induction of ER stress as well as NSCLC growth in vitro. CONCLUSION: Our findings suggest that the induction of proteotoxicity provides a promising new target for developing anticancer drugs. Copyright
Authors: Diarmuid M Moran; Patricia B Trusk; Karen Pry; Keren Paz; David Sidransky; Sarah S Bacus Journal: Mol Cancer Ther Date: 2014-03-31 Impact factor: 6.261
Authors: Danijela Maksimovic-Ivanic; Paolo Fagone; James McCubrey; Klaus Bendtzen; Sanja Mijatovic; Ferdinando Nicoletti Journal: Int J Cancer Date: 2017-01-20 Impact factor: 7.396
Authors: S Kawabata; J J Gills; J R Mercado-Matos; J Lopiccolo; W Wilson; M C Hollander; P A Dennis Journal: Cell Death Dis Date: 2012-07-19 Impact factor: 8.469
Authors: Gideon M Blumenthal; Joell J Gills; Marc S Ballas; Wendy B Bernstein; Takefumi Komiya; Roopa Dechowdhury; Betsy Morrow; Hyejeong Root; Guinevere Chun; Cynthia Helsabeck; Seth M Steinberg; Jaclyn LoPiccolo; Shigeru Kawabata; Erin R Gardner; William D Figg; Phillip A Dennis Journal: Oncotarget Date: 2014-09-30
Authors: Charlotte E Johnson; David K Hunt; Marie Wiltshire; Terry P Herbert; Julian R Sampson; Rachel J Errington; D Mark Davies; Andrew R Tee Journal: Mol Oncol Date: 2014-11-22 Impact factor: 6.603